The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Corticosteroid use and outcomes in patients with biliary tract cancer
Findings from the TOPAZ-1 trial (NCT03875235) has established that corticosteroids negatively impact patients with biliary tract cancer (BTC). Federica Lo Prinzi, MD, Fondazione Policlinico Universitario Campus Bio- Medico, Rome, Italy, gives an overview of a large international real-world analysis evaluating the impact of concomitant medications on patients with advanced biliary tract cancers (BTCs). The study confirmed that patients receiving corticosteroids prior to therapy experienced shorter survival compared with those who did not, while no major differences were observed in response rates or safety. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know thanks to the TOPAZ-1 that the corticosteroids have a negative impact on survival outcome of patients. In fact, in the clinical trial, this type of patients were excluded. So in our analysis we highlighted this problem and we know that the patients who took corticosteroids have worse overall survival and progression-free survival.
This transcript is AI-generated...
We know thanks to the TOPAZ-1 that the corticosteroids have a negative impact on survival outcome of patients. In fact, in the clinical trial, this type of patients were excluded. So in our analysis we highlighted this problem and we know that the patients who took corticosteroids have worse overall survival and progression-free survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
